EMA Number 
(Invented) 
name 
Strength  Pharmaceutical 
Form 
Route of 
Administration 
Immediate 
Packaging 
Content 
(concentration) 
Pack size 
EU/1/23/1740/001 
AREXVY   
--¹ 
EU/1/23/1740/002 
AREXVY   
--¹ 
Powder and 
suspension for 
suspension for 
injection 
Powder and 
suspension for 
suspension for 
injection 
Intramuscular 
use 
Intramuscular 
use 
powder: vial 
(glass); 
suspension: vial 
(glass) 
powder: vial 
(glass); 
suspension: vial 
(glass) 
powder: 120 µg; 
suspension: 0.5 
ml 
1 powder vial + 
1 suspension 
vial  
powder: 120 µg; 
suspension: 0.5 
ml 
10 powder vials 
+ 10 suspension 
vials  
--¹ 
--¹  
After reconstitution, one dose (0.5 mL) contains: 
RSVPreF3¹ antigen²,³ 120 micrograms 
¹ Respiratory Syncytial Virus recombinant glycoprotein F stabilised in the pre-fusion conformation = RSVPreF3 
² RSVPreF3 produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology  
³ adjuvanted with AS01E containing: 
plant extract Quillaja saponaria Molina, fraction 21 (QS-21)    25 micrograms 
3-O-desacyl-4’-monophosphoryl lipid A (MPL) from Salmonella minnesota 
 25 micrograms 
 
 
 
 
 
 
 
